Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis
- PMID: 26498903
- DOI: 10.1016/j.pedhc.2015.07.010
Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis
Abstract
Cystic fibrosis (CF) affects several organs, most notably the lungs, which become predisposed to infections with potentially severe consequences. Because of physiologic changes and infection characteristics, unique approaches to antimicrobial agent selection, dosing, and administration are needed. To provide optimal acute and long-term care, pediatric health care providers must be aware of these patient features and common approaches to antimicrobial therapy in CF, which can differ significantly from those of other infectious diseases. The purpose of this article is to review common respiratory pathogens, pharmacology of commonly used antimicrobial agents, and unique pharmacokinetics and dosing strategies often used when treating children with CF.
Keywords: CF; Cystic Fibrosis ID Pharmacology; Cystic Fibrosis ID Pharmacotherapy.
Copyright © 2015 National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.
Similar articles
-
[Antibiotic inhalation in cystic fibrosis. A review of the literature].Monatsschr Kinderheilkd. 1991 Feb;139(2):73-80. Monatsschr Kinderheilkd. 1991. PMID: 1903843 Review. German.
-
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.Eur Respir J. 2005 Sep;26(3):458-61. doi: 10.1183/09031936.05.00009605. Eur Respir J. 2005. PMID: 16135728
-
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.Curr Opin Infect Dis. 2015 Dec;28(6):547-56. doi: 10.1097/QCO.0000000000000217. Curr Opin Infect Dis. 2015. PMID: 26524327 Review.
-
Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.J Cyst Fibros. 2015 Jan;14(1):111-9. doi: 10.1016/j.jcf.2014.06.003. Epub 2014 Aug 1. J Cyst Fibros. 2015. PMID: 25091537 Clinical Trial.
-
Eradication of Pseudomonas aeruginosa in cystic fibrosis.Eur Respir J. 2006 Feb;27(2):438-9. doi: 10.1183/09031936.06.00118805. Eur Respir J. 2006. PMID: 16452606 No abstract available.
Cited by
-
Comparison of respiratory pathogen colonization and antimicrobial susceptibility in people with cystic fibrosis bronchiectasis versus non-cystic fibrosis bronchiectasis: a protocol for a systematic review.Syst Rev. 2021 Jan 4;10(1):7. doi: 10.1186/s13643-020-01557-6. Syst Rev. 2021. PMID: 33397475 Free PMC article.
-
Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides.J Manag Care Spec Pharm. 2021 Feb;27(2):157-165. doi: 10.18553/jmcp.2021.27.2.157. J Manag Care Spec Pharm. 2021. PMID: 33506732 Free PMC article.
-
Dental treatment for people with cystic fibrosis.Eur Arch Paediatr Dent. 2016 Jun;17(3):195-203. doi: 10.1007/s40368-016-0229-9. Epub 2016 May 4. Eur Arch Paediatr Dent. 2016. PMID: 27146508 Review.
-
Review of Tobramycin Dosing in Pediatric Patients With Cystic Fibrosis.J Pediatr Pharmacol Ther. 2023;28(1):63-70. doi: 10.5863/1551-6776-28.1.63. Epub 2023 Feb 3. J Pediatr Pharmacol Ther. 2023. PMID: 36777977 Free PMC article.
-
Anti-infectives in Pediatric Patients with Cystic Fibrosis: A Comprehensive Review of Population Pharmacokinetic Analyses.Clin Pharmacokinet. 2025 May;64(5):631-653. doi: 10.1007/s40262-025-01505-4. Epub 2025 Apr 21. Clin Pharmacokinet. 2025. PMID: 40254714 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical